GSK plc (GSK.L) — Company Research

Last Updated: 18 May 2026

GSK plc is a London-headquartered, FTSE 100-listed biopharmaceutical group that researches, develops and manufactures vaccines, specialty medicines and general medicines, organised across two reporting segments described in the source dataset as Commercial Operations and Total R&D. The company's portfolio spans Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis and HPV vaccines; specialty medicines for HIV, respiratory eosinophil-driven disease, lupus / lupus nephritis, ovarian cancer, endometrial cancer and oncology more broadly; and general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis and inflammatory skin disease. For FY2025 (year ended 31 December 2025) GSK reported revenue of £32,667 million, operating income of £8,338 million, net income of £5,716 million, free cash flow of £4,756 million and diluted earnings per share of £1.388 — a year in which net income more than doubled (+£3,141 million YoY, EPS growth +123.15%) on a comparable revenue base, after FY2024 net income had compressed to £2,575 million. The stock trades in pence on the LSE under GSK.L; intraday on 18 May 2026 the price stood at 1,862.5p, capitalising the equity at £74.78 billion. This research note assembles GSK's reported financial profile, the recent news flow and the on-calendar events using only the company's own dataset and primary news URLs, with no analyst opinions or price targets included. Note: the dataset for this report contains no SEC 10-K or 20-F filing — GSK is UK-incorporated, reports under IFRS via its UK Annual Report and London Stock Exchange RNS notices, and the US-listed ADR (NYSE:GSK) files an annual 20-F that is outside the scope of this dataset. Therapeutic-area-level revenue splits (Specialty Medicines / Vaccines / General Medicines), product-by-product revenue, geographic revenue mix (US / Europe / International), R&D pipeline-by-asset commentary and the detailed MD&A narrative that would normally be sourced from a 10-K / 20-F are therefore not quoted in this report; readers should consult GSK's investor-relations page at https://www.gsk.com directly for those breakdowns.

1. Company Snapshot

Name	GSK plc (formerly GlaxoSmithKline plc; renamed May 2022)
Ticker	GSK.L (London Stock Exchange); also NYSE:GSK (US ADR)
Sector / Industry	Healthcare / Drug Manufacturers - General
Country of incorporation	United Kingdom
Reporting currency	British pound (GBP)
Trading currency (LSE)	British pence (GBp)
Market cap	£74.78 billion
Enterprise value	£90.11 billion
Latest fiscal-year revenue	£32,667 million (FY2025, ended 31 December 2025)
Employees	66,841
CEO (per source data)	Mr. Luke Victor Miels
Headquarters	79 New Oxford Street, London, United Kingdom
Website	gsk.com
Price (intraday 18 May 2026)	1,862.5p
Previous close	1,872.5p
Day range	1,855.5p – 1,900.0p
52-week high	2,282.0p
52-week low	1,288.605p
Beta	0.298
Dividend yield (trailing)	3.65%
Founded	1715 (GSK plc name adopted May 2022)

2. Bull Case vs Bear Case

Bull case (factual distillation from the source dataset):

• Earnings have recovered sharply on a flat-ish revenue base. Revenue rose from £29,324m in FY2022 to £30,328m in FY2023 (+3.42%), to £31,376m in FY2024 (+3.46%) and to £32,667m in FY2025 (+4.11%); over the same window net income (heavily influenced by exceptional items not separately disclosed in the source dataset — notably the FY2022 figure of £14,956m, which is well above operating income that year of £6,729m) moved £14,956m → £4,928m → £2,575m → £5,716m, with FY2025 EPS growth of +123.15% reported in the dataset's eps_growth_yoy field.
• Free cash flow generation is solid: £5,145m (FY2022), £4,424m (FY2023), £3,572m (FY2024) and £4,756m (FY2025), funding both the £2,564m FY2025 dividend and the £1,377m of share buybacks recorded for FY2025 (the FY2023 and FY2024 buyback fields are reported as zero in the dataset).
• Margins are characteristic of a patent-protected, vaccines-and-specialty pharma franchise: gross margin 72.4% and operating margin 25.52% (FY2025; JSON ratios), with net margin 17.5%, return on equity 34.9% and return on assets 9.35%.
• The pipeline news flow over the last six weeks has been active: completion of the US$950m acquisition of 35Pharma Inc. (per Insider Monkey via Yahoo Finance, 3 May 2026) bringing the HS235 candidate into GSK's pipeline; UK approval for Lynavoy (linerixibat) in primary biliary cholangitis (per Simply Wall St. via Yahoo Finance, 3 May 2026); and an exclusive China commercialisation alliance for bepirovirsen with Sino Biopharmaceutical subsidiary CTTQ following priority regulatory review status in China (per Simply Wall St. via Yahoo Finance, 12 May 2026).
• Trailing dividend yield of 3.65% on a £74.78 billion market cap implies a cash distribution of approximately £2.73 billion across the trailing window — broadly aligned with the £2,564m of dividends actually paid in FY2025.
• Beta of 0.298 (JSON) is materially below the market — historically, large-cap European pharma has traded as a defensive equity, which the source dataset's beta reading reflects.

Bear case (factual distillation from the source dataset):

• The 52-week range is wide and the stock currently sits well below the high. The 52-week high is 2,282.0p versus the 18 May 2026 intraday price of 1,862.5p — i.e. shares are about 18.4% below the 52-week high. Recent news coverage (Simply Wall St. via Yahoo Finance, 3 May 2026) characterised the recent move as "share price weakness," noting "a 11.3% 1 month share price decline, despite a 3.8% year to date share price gain and a 36.6% 1 year total shareholder return."
• Operating cash flow swung lower in FY2024 (£6,554m, down from £6,768m in FY2023) before recovering to £7,741m in FY2025, while capex was steady at £2,985m in FY2025 (£2,982m in FY2024); the resulting FCF compression in FY2024 to £3,572m partially reflects this.
• The balance sheet is debt-heavy by some measures: total debt £17,720m versus total equity £16,377m at year-end 2025 (D/E 1.082), and the current ratio of 0.82 (current assets £17,510m vs current liabilities £21,391m) means working-capital coverage is below 1.0 at the reporting date.
• Cash and equivalents fell from £3,693m at year-end 2024 to £3,150m at year-end 2025.
• The trailing P/E figure in the dataset's ratios.pe_trailing field reads 1,341.86×, which is mechanically distorted by a unit mismatch — the calculation divides the GBp-denominated share price (1,862.5p) by the GBP-denominated diluted EPS (£1.388) without normalising. The yfinance trailing P/E of 13.12× is the value to use; the forward yfinance P/E of 9.53× implies a step-down in expected next-twelve-month earnings versus the trailing window (no analyst-consensus number is separately quoted in this report).
• Pipeline setback risk is live: per Simply Wall St. via Yahoo Finance, 3 May 2026, GSK and Alector discontinued their Phase 2 Alzheimer's trial after the study failed to meet efficacy goals, "effectively end[ing] a high profile collaboration in neurodegenerative research between the two companies."
• The earlier price-discovery point — the May 2022 demerger of Haleon (the consumer healthcare business) which produced a large one-off accounting gain in FY2022 — is not separately disclosed within the source dataset; FY2022 reported net income of £14,956m and EPS of £3.662 should therefore be treated with care as base-period comparators.

3. What Does This Company Actually Do?

Per the dataset's company description, GSK plc "engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally," operating "through Commercial Operations and Total R&D segments." The product line, again per the dataset's company description, is:

• Specialty medicines — oncology (ovarian cancer, endometrial cancer); respiratory / immunology / inflammation; inhaled HIV medicines; respiratory eosinophil-driven disease therapies; lupus and lupus nephritis treatments.
• Vaccines — Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria / Tetanus / Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles / Mumps / Rubella / Chickenpox, and Human Papilloma Virus.
• General medicines — asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions.
• Other — oral small-molecule therapies in oncology and inflammatory diseases, and partnership work including a collaboration with CureVac to develop mRNA vaccines for infectious diseases and a strategic alliance with AN2 Therapeutics, Inc. for new TB therapies.

Specific FY2025 revenue percentages by therapeutic area, by individual product or by geography are not disclosed within this report's source dataset. A 10-K / 20-F extract was not made available for this run, and the JSON does not carry segment-level revenue percentages. GSK's segment-by-segment breakdown is published in the company's UK Annual Report; readers needing the precise specialty-medicines / vaccines / general-medicines split, or the US / Europe / International split, should consult GSK's investor-relations page at https://www.gsk.com directly. Because fewer than two segment percentages can be quoted from the source data, no Revenue Mix Donut visualisation is constructed in this report.

What can be confirmed from the JSON is consolidated revenue of £32,667 million in FY2025, +4.11% YoY, generated against a cost of revenue of £9,017 million for a gross profit of £23,650 million and a 72.4% gross margin.

4. The Business Model

GSK's business model is the standard branded-pharma / vaccines model: invest sustained R&D into a portfolio of proprietary medicines and vaccines, secure regulatory approvals and patent protection across major markets, manufacture at scale, and capture economic rents over the patent-protected portion of each product's life. The visible financial fingerprint of that model in the source dataset:

• Gross margin of 72.4% in FY2025 (£23,650m gross profit on £32,667m revenue) — characteristic of a vaccines-and-specialty-medicines mix in which cost of goods is materially below revenue once the asset is approved and at scale.
• Operating margin of 25.52% in FY2025 (£8,338m operating income on £32,667m revenue) — the gap between gross and operating margins is absorbed by R&D and selling, general & administrative expense, which together totalled £15,312m in FY2025 (per the JSON operating_expenses line). The exact R&D / SG&A split is not separately disclosed in the dataset.
• Net margin of 17.5% — net income of £5,716m on £32,667m revenue, with the gap between operating income (£8,338m) and net income (£5,716m) reflecting £687m of interest expense and a 15.0% effective tax rate (£1,112m tax provision on £7,401m pretax income).
• Capital intensity is moderate. Capex of £2,985m in FY2025 represents 9.1% of revenue — meaningful, but below the 10–15% capex/revenue ratios typical of capacity-build phases at semiconductor or EV peers. Operating cash flow of £7,741m comfortably funded capex, with £4,756m of free cash flow remaining for distribution to shareholders (£2,564m dividend, £1,377m buybacks in FY2025, totalling £3,941m returned to shareholders against £4,756m FCF — an 82.9% cash payout ratio for the year).

Subsidy / regulatory-credit dependency. There is no "subsidy" or "regulatory credit" line in the source dataset — GSK's revenue is paid for by health systems, payers, governments and patients buying medicines and vaccines at negotiated prices, rather than by tax credits in the way an EV-credit or clean-energy revenue line might be. Pricing concessions, mandatory rebates and pharmaceutical-industry-fee programmes inherent to government-payer contracting in the US (Medicare, Medicaid), UK (NHS) and Europe are intrinsic features of the industry but are not quantified as a separate line within the source dataset for this report.

Moat features visible in the dataset. The patent-protected nature of branded medicines; the manufacturing complexity of biologic and vaccine production (FluMist / Shingrix / Arexvy-class assets); a global commercial footprint across the UK, US and international markets; and an R&D engine that is funded by current-period operating cash flow. Specific patent counts, expiry schedules and biosimilar-erosion exposure are not enumerated in the source dataset and should be read from the UK Annual Report.

5. Financial Health

Annual P&L and balance sheet (GBP millions; per the JSON financials_annual block):

FY (Dec)	Revenue	Gross profit	Operating income	Net income	Diluted EPS	OCF	FCF	Total debt	Total equity	Cash & equiv.	Buybacks	Dividends paid
2022	29,324	19,770	6,729	14,956	£3.662	7,403	5,145	20,987	10,598	3,523	not disclosed	3,467
2023	30,328	21,763	7,345	4,928	£1.199	6,768	4,424	18,018	13,347	2,746	0	2,247
2024	31,376	22,328	5,542	2,575	£0.622	6,554	3,572	16,986	13,671	3,693	0	2,444
2025	32,667	23,650	8,338	5,716	£1.388	7,741	4,756	17,720	16,377	3,150	1,377	2,564

FY2021 is not populated in the source data — the JSON returns null for the year's P&L, balance-sheet and cash-flow rows.

Revenue growth YoY: FY2023 +3.42%, FY2024 +3.46%, FY2025 +4.11% (JSON revenue_growth_yoy). EPS growth YoY: FY2023 −67.26%, FY2024 −48.12%, FY2025 +123.15% (JSON eps_growth_yoy). FY2022's reported net income of £14,956m sits above that year's operating income of £6,729m, indicating that FY2022's bottom line included substantial below-the-line exceptional items not separately disclosed within the source dataset — FY2022 net income / EPS should therefore be treated as a non-comparable comparator.

Share count has been relatively stable: diluted shares 4,084m (FY2022), 4,111m (FY2023), 4,142m (FY2024), 4,117m (FY2025) — a modest reduction in FY2025 consistent with the £1,377m of FY2025 buybacks recorded in the source dataset.

Quarterly trend (GBP millions; per the JSON financials_quarterly block):

Quarter end	Revenue	Gross profit	Operating income	Net income	Diluted EPS	OCF	FCF
31 Mar 2025	7,516	5,579	2,216	1,624	£0.393	1,145	697
30 Jun 2025	7,986	5,821	2,023	1,443	£0.351	2,096	1,463
30 Sep 2025	8,547	6,289	2,593	2,013	not disclosed	2,222	1,343
31 Dec 2025	8,618	5,961	1,506	636	£0.156	2,278	1,253
31 Mar 2026	7,629	5,754	2,293	1,737	£0.426	1,141	698

Implied gross margin by quarter: Q1 2025 74.2%, Q2 2025 72.9%, Q3 2025 73.6%, Q4 2025 69.2%, Q1 2026 75.4% (calculated as gross_profit / revenue from the JSON quarterly rows). Q4 2025 saw the lowest gross margin of the five-quarter window alongside the highest revenue print (£8,618m) and the lowest net income (£636m, £0.156 diluted EPS) — i.e. a Q4 in which operating income compressed (£1,506m, the lowest quarter in the window) despite peak revenue, consistent with seasonality / year-end charge patterns that are not separately attributed in the source data.

0 2.5 5.0 7.5 10.0

0% 25% 50% 75% 100%

£7.52

£7.99

£8.55

£8.62

£7.63

74.2%

Q1 25 Q2 25 Q3 25 Q4 25 Q1 26

Revenue (£bn) Gross Margin (%)

Revenue Gross Margin

Cash, debt and capital return:

• Operating cash flow rose to £7,741m in FY2025 from £6,554m in FY2024 (+18.1%), while capex of £2,985m was effectively flat versus £2,982m the prior year — translating into FCF of £4,756m, up from £3,572m in FY2024.
• Cumulative FY2022–FY2025 free cash flow totals £17,897m (£5,145m + £4,424m + £3,572m + £4,756m).
• Cumulative dividends paid across FY2022–FY2025: £10,722m (£3,467m + £2,247m + £2,444m + £2,564m).
• Buybacks: not disclosed for FY2022 in the source data; reported as zero for FY2023 and FY2024; £1,377m for FY2025.
• Total debt edged up from £16,986m (FY2024) to £17,720m (FY2025), of which £14,015m is classified as long-term. Cash and equivalents fell from £3,693m to £3,150m year-on-year.
• Total equity climbed from £13,671m to £16,377m year-on-year, taking debt-to-equity down from 1.24× (FY2024) to 1.08× (FY2025) on a like-for-like calculation using JSON balance-sheet figures.

6. Valuation & Market Data

All figures from the JSON price and ratios blocks as of the 18 May 2026 data snapshot.

Last price (intraday)	1,862.5p
Previous close	1,872.5p
Day open	1,880.0p
Day high / low	1,900.0p / 1,855.5p
52-week high / low	2,282.0p / 1,288.605p
Volume (session, partial)	11,082,277
10-day average volume	8,860,529
Market cap	£74.78 billion
Enterprise value	£90.11 billion
Shares outstanding	4,015,024,374
Float	3,891,520,800 (96.9% of shares outstanding)
P/E trailing (yfinance)	13.12×
P/E forward (yfinance)	9.53×
P/E trailing (raw ratios.pe_trailing)	1,341.86× — distorted by GBp price / GBP EPS unit mismatch; not a usable figure
P/B (market cap / equity)	4.57×
P/S trailing	2.29×
EV / Revenue	2.76×
EV / EBITDA proxy	10.81× (D&A not separately disclosed in dataset; proxy uses operating income)
FCF yield	6.36% (£4,756m / £74.78bn market cap)
Gross margin	72.4%
Operating margin	25.52%
Net margin	17.50%
Return on equity	34.9%
Return on assets	9.35%
Debt / Equity	1.082
Current ratio	0.82
Dividend yield (trailing)	3.65%
Beta	0.298

Short-interest figures (shares short, % of float, days to cover) and put / call ratios are not present in the source dataset — not disclosed in this report's source data.

No analyst price targets, buy / sell / hold ratings or consensus estimates are included in this report, per editorial rule.

7. What Are They Building / What's Coming?

The most recent pipeline and corporate-development news flow visible in the source dataset, by date:

• China — bepirovirsen for chronic hepatitis B. Per Simply Wall St. via Yahoo Finance, 12 May 2026 (https://finance.yahoo.com/sectors/healthcare/articles/gsk-china-hepatitis-b-alliance-090945868.html): "GSK (LSE:GSK) has entered a partnership with Sino Biopharmaceutical's subsidiary CTTQ to launch and commercialize its hepatitis B treatment, bepirovirsen, in China. Bepirovirsen has received priority regulatory review status in China following Phase III trial results. The collaboration focuses on accelerating patient access to bepirovirsen across China's large chronic hepatitis B population." Per the same article, GSK at the time of writing was trading "at around £18.445, has returned 37.2% over the past year and 63.6% over the past five [years]."
• 35Pharma acquisition — completed. Per Insider Monkey via Yahoo Finance, 3 May 2026 (https://finance.yahoo.com/sectors/healthcare/articles/gsk-gsk-completes-950m-acquisition-075214045.html): "GSK plc (NYSE:GSK) stated on April 15 that it had completed the acquisition of 35Pharma Inc., a private clinical-stage biopharmaceutical firm based in Canada. The $950 million purchase gives GSK plc (NYSE:GSK) complete control of 35Pharma and its pipeline, which includes HS235."
• Lynavoy (linerixibat) — UK approval. Per Simply Wall St. via Yahoo Finance, 3 May 2026 (https://finance.yahoo.com/sectors/healthcare/articles/gsk-juggles-alzheimer-setback-leadership-011900077.html): "GSK received UK approval for Lynavoy (linerixibat) to treat primary biliary cholangitis."
• Alzheimer's Phase 2 — discontinued with Alector. Per the same Simply Wall St. article, 3 May 2026: "GSK (LSE:GSK) and Alector have discontinued their phase 2 trial of an Alzheimer's drug candidate after the study did not meet efficacy goals. The decision effectively ends a high profile collaboration in neurodegenerative research between the two companies."
• Existing R&D collaborations (per the dataset's company description). GSK has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases, and a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB.

Detailed pipeline-by-asset disclosure — the full enumerated list of programmes by phase across oncology, vaccines, respiratory / immunology, HIV and rare-disease portfolios — is normally found in GSK's UK Annual Report or its 20-F filing. The dataset for this report does not contain an SEC 10-K or 20-F extract, so a programme-by-programme phase table is not constructed here; readers should refer to GSK's investor-relations page at https://www.gsk.com directly. Patent-filing counts, AI / data-centre / supercomputing infrastructure investments and custom-silicon programmes are not disclosed in this report's source data.

8. Competitive Landscape

GSK competes across multiple distinct product domains, each with a different competitor set. The main competitors in each domain, drawn from the same global large-pharma universe disclosed in primary sources (rather than a per-product market-share dataset, which is not present in the JSON):

Domain	Primary competitors
Vaccines (Shingles, RSV, HPV, influenza, paediatric combinations)	Merck & Co., Pfizer, Sanofi, Moderna, AstraZeneca
HIV (long-acting injectables, oral combinations)	Gilead Sciences, ViiV Healthcare partners
Respiratory / Immunology (asthma, COPD, eosinophilic disease)	AstraZeneca, Sanofi/Regeneron, Roche, Amgen
Oncology (ovarian, endometrial, haematology)	AstraZeneca, Merck & Co., Bristol-Myers Squibb, Roche, Pfizer, Novartis
Inflammation / lupus / rare disease	AstraZeneca (Alexion), Roche, AbbVie, Sanofi
General medicines (asthma, COPD generics)	Generic / biosimilar producers globally

Named, citable market-share percentages for any of these competitor sets are not present in the source dataset, so a Competitor Share visualisation is not constructed here. The principal third-party share datasets that would underpin such a chart — IQVIA prescription audits, Evaluate Pharma sales rankings, vaccine market-share publications from public-health authorities — sit outside this report's source-of-truth boundary.

What can be characterised qualitatively from the source data is GSK's positioning within UK-listed large pharma: the company sits alongside AstraZeneca PLC in the FTSE 100 large-pharma cohort, with GSK biased structurally toward vaccines and HIV and AstraZeneca biased toward oncology and rare disease — a contrast meaningful to investors comparing the two London-listed names. Cross-reference: the AstraZeneca PLC company research note from the same dataset cohort describes AstraZeneca's FY2025 revenue of $58,739m, gross margin 81.9%, operating margin 22.69%, against GSK's FY2025 revenue of £32,667m, gross margin 72.4% and operating margin 25.52%.

9. Leadership and Ownership

Senior leadership. The CEO listed in the source dataset is Mr. Luke Victor Miels. The dataset does not include a separate roster of additional executive officers, board composition, or pay disclosures — these are normally found in the UK Annual Report / Notice of AGM and the SEC 20-F. The 3 May 2026 Simply Wall St. article (URL above) noted that GSK "has also appointed Roanne Parry as Chief People Officer, a move that may shape its global people and culture agenda."

Top institutional holders (per the JSON holders.institutional_top block):

Holder	Shares	% held	Reported value	As of
Aristotle Capital Management, LLC	3,005,874	0.07%	$5.60 bn (per dataset)	31 Dec 2025
Pacer Advisors, Inc.	1,958,928	0.05%	$3.65 bn (per dataset)	31 Mar 2026
Paradigm Asset Management Company, LLC	65,976	0.00%	$122.88 m (per dataset)	31 Mar 2026
Generali Investments Cee, Investicni Spolecnost, A.s.	38,314	0.00%	$71.36 m (per dataset)	31 Mar 2026

The institutional-holders feed in this dataset is sparse and dominated by smaller US-based institutional positions in the ADR; the principal UK index holders (BlackRock, Vanguard, State Street, Capital Group, Norges Bank, etc.) that would normally dominate the top of a FTSE 100 register are not present in the source data here. Readers needing the authoritative GSK holder register should consult the UK Annual Report / TR-1 disclosures filed via RNS. The "reported value" figures appear unusually large relative to the share count (e.g. Aristotle Capital's 3.01m shares would be worth approximately £56m at the 18 May 2026 intraday price of 1,862.5p, not the $5.60bn shown in the dataset's value field) — the value column should therefore be treated as unreliable in this dataset, and shares-and-percentage used instead.

Recent insider / corporate transactions (per the JSON holders.insider_transactions block, most recent 10 rows):

Reporter	Date	Shares	Reported value
GSK Plc	30 Apr 2026	0	not disclosed in source data
Becker (Wendy)	29 Apr 2026	4,000	£105,788
Dodge & Cox	28 Apr 2026	10,419,834	not disclosed in source data
Brown (Julie)	27 Apr 2026	243,880	not disclosed in source data
GSK Plc	22 Apr 2026	965,671	£27,130,526
GSK Plc	21 Apr 2026	335,000	£9,515,005
GSK Plc	20 Apr 2026	330,000	£9,560,760
GSK Plc	17 Apr 2026	330,000	£9,481,230
GSK Plc	16 Apr 2026	330,000	£9,483,540
GSK Plc	15 Apr 2026	325,000	£9,606,025

The buy/sell direction, open-market-versus-pre-planned characterisation and the role of each reporter are not populated in the source dataset's insider-transactions block. The cluster of "GSK Plc" reporter rows from 15–22 April 2026 — consistently in the 325,000–965,671 share-per-day range, with total reported value approximately £84.78m across the seven dated rows — is consistent in form with the company's announced share-buyback programme executing through the market: an authorised on-market repurchase agent buying back stock daily and filing the daily-purchase RNS notice. The Becker (Wendy), Dodge & Cox and Brown (Julie) rows appear to represent third-party holdings notifications or director-related transactions; the source dataset does not disambiguate. Readers wanting the authoritative characterisation should consult the daily share-buyback announcements and TR-1 / PDMR notices filed via the London Stock Exchange RNS service.

10. Risks and Challenges

A 10-K / 20-F extract was not available for this report's source data; a structured, per-bullet "Risk Factors" enumeration from the company's own filing is therefore not reproduced here. Readers needing the company's own enumerated risk-factor disclosure should consult the 20-F filed with the SEC and the principal-risks section of the UK Annual Report at https://www.gsk.com directly. The following structural risks are visible from the JSON dataset, the recent news flow and standard features of branded-pharma issuers:

• Pipeline and trial-failure risk. Per the 3 May 2026 Simply Wall St. article (URL in Section 7), the discontinuation of the GSK / Alector Phase 2 Alzheimer's trial after failure to meet efficacy goals is a recent, concrete example of pipeline attrition. Vaccine and specialty-medicine pipelines carry binary clinical-readout risk by nature, and discontinuations are a recurring feature of the business.
• Patent-cliff and biosimilar / generic erosion. Branded pharma's earnings power is bounded by the patent-protected window of each product. Specific patent-expiry dates and biosimilar / generic exposure schedules for GSK's portfolio are not enumerated in this report's source dataset.
• Regulatory approval and post-marketing risk. Per the same 3 May 2026 article, UK approval for Lynavoy (linerixibat) in primary biliary cholangitis is the most recent dated regulatory data point. Approvals can be denied, delayed, conditioned on post-approval studies, or subsequently restricted on safety grounds; revenue ramp on newly approved products is exposed to these events.
• Pricing and reimbursement pressure. Branded-pharma issuers face statutory rebate and pricing regimes in major payer markets (Medicare, Medicaid, US Inflation Reduction Act drug-price negotiation, NHS / NICE in the UK, country-by-country pricing in Europe). The cost of these programmes to GSK is not separately quantified in the source dataset.
• Litigation exposure. Branded-pharma litigation — product liability, patent disputes, government investigations, antitrust actions — is a structural feature of the industry. The source dataset does not enumerate active matters; readers should consult the company's filings directly.
• Balance-sheet leverage and working-capital tightness. Total debt of £17,720m versus total equity of £16,377m at year-end 2025 (D/E 1.08×) and a current ratio of 0.82 mean the balance sheet runs with limited working-capital cushion and meaningful debt service; interest expense was £687m in FY2025 against £8,338m of operating income (interest coverage 12.1×).
• Geographic concentration and FX. GSK reports in GBP but generates a material share of revenue outside the UK; exact geographic splits are not disclosed in this report's source data, but FX translation can materially affect reported figures from period to period.
• Acquisition integration risk. The recent US$950m 35Pharma acquisition (announced complete 15 April 2026 per the 3 May 2026 Insider Monkey article) is the latest example; integration risk and asset-impairment risk are inherent in the bolt-on-deals strategy.
• China and emerging-market policy risk. The 12 May 2026 announcement of the bepirovirsen / CTTQ China commercialisation alliance (per Simply Wall St., URL above) creates a meaningful policy-exposure to Chinese regulatory and reimbursement decisions for that asset.

11. Recent Developments

Most recent first — last 6 weeks of GSK-specific news from the source dataset's recent_news block:

• 12 May 2026 — Simply Wall St. via Yahoo Finance: "GSK China Hepatitis B Alliance Puts Bepirovirsen And Valuation In Focus." GSK entered a partnership with Sino Biopharmaceutical's subsidiary CTTQ to launch and commercialise bepirovirsen for chronic hepatitis B in China; bepirovirsen has received priority regulatory review status in China following Phase III trial results. The article notes GSK was trading at around £18.445 at the time of publication, with a 37.2% one-year return and 63.6% five-year return. URL: https://finance.yahoo.com/sectors/healthcare/articles/gsk-china-hepatitis-b-alliance-090945868.html
• 6 May 2026 — Simply Wall St. via Yahoo Finance: "GSK's (LON:GSK) Performance Is Even Better Than Its Earnings Suggest." General commentary noting that investors were "underwhelmed by the solid earnings posted by GSK plc (LON:GSK) recently." URL: https://finance.yahoo.com/markets/stocks/articles/gsks-lon-gsk-performance-even-052511140.html
• 3 May 2026 — Simply Wall St. via Yahoo Finance: "A Look At GSK (LSE:GSK) Valuation After Recent Share Price Weakness And Pipeline Developments." Characterises GSK as having seen "an 11.3% 1 month share price decline, despite a 3.8% year to date share price gain and a 36.6% 1 year total shareholder return." URL: https://finance.yahoo.com/markets/stocks/articles/look-gsk-lse-gsk-valuation-210624898.html
• 3 May 2026 — Insider Monkey via Yahoo Finance: "GSK (GSK) Completes $950M Acquisition to Expand Drug Pipeline." Per the article, GSK stated on 15 April 2026 that it had completed the acquisition of 35Pharma Inc., a Canadian private clinical-stage biopharmaceutical firm; the US$950 million purchase gives GSK complete control of 35Pharma and its pipeline including HS235. URL: https://finance.yahoo.com/sectors/healthcare/articles/gsk-gsk-completes-950m-acquisition-075214045.html
• 3 May 2026 — Simply Wall St. via Yahoo Finance: "GSK Juggles Alzheimer's Setback And Leadership Shift With Product Progress." Three GSK-specific items in one article: (1) GSK and Alector discontinued their Phase 2 Alzheimer's trial after the study did not meet efficacy goals, "effectively end[ing] a high profile collaboration in neurodegenerative research between the two companies"; (2) UK approval for Lynavoy (linerixibat) to treat primary biliary cholangitis; (3) appointment of Roanne Parry as Chief People Officer. URL: https://finance.yahoo.com/sectors/healthcare/articles/gsk-juggles-alzheimer-setback-leadership-011900077.html

Other items in the dataset's recent_news block (8 May 2026 IBD article on biotech IBD-50 names; 8 May 2026 Zacks article on Gilead Q1; 4 May 2026 Zacks article on Summit Therapeutics; 1 May 2026 Zacks article on Gilead pre-earnings; 30 April 2026 Zacks article on Ionis Q1) are not GSK-specific corporate events and are not summarised here.

The 18 May 2026 share price of 1,862.5p sits approximately 0.9% below the 12 May 2026 reference level of ~£18.445 (1,844.5p) noted in the Simply Wall St. China-alliance article — i.e. a roughly flat-to-marginally-up move across the six days between the alliance announcement and the report date, after a six-week period that was characterised in source-data news coverage as one of "share price weakness."

12. Key Dates Coming Up

Date	Event
14 May 2026	Ex-dividend date (per the JSON calendar.ex_dividend_date field — has now passed by the 18 May 2026 data snapshot)
29 July 2026	Next earnings release (Q2 / H1 2026; per the JSON calendar.next_earnings_date field)
Dividend pay date	Not disclosed in the source dataset
AGM date	Not disclosed in the source dataset
Regulatory decision dates / product-launch milestones	Not disclosed in the source dataset — see GSK investor calendar at https://www.gsk.com

---

Source-of-truth notes

• Primary market and fundamentals data: source-data snapshot generated 18 May 2026 at 05:00 UTC (JSON: yfinance feed; ticker GSK.L; reporting currency GBP).
• No SEC 10-K or 20-F extract was supplied for this run; therapeutic-area revenue splits, geographic revenue mix, R&D pipeline-by-asset programme tables and MD&A narrative are therefore not quoted in this report. Readers needing those breakdowns should consult GSK plc's UK Annual Report and 20-F filing directly via https://www.gsk.com and the SEC EDGAR system.
• News URLs in Section 11 are taken byte-for-byte from the source-data recent_news records.
• Insider / corporate-transaction characterisations in Section 9 are inferred from the JSON-supplied reporter names and dates; the dataset does not include explicit buy / sell / pre-planned-versus-discretionary fields.

Related links: Live Charts — Economic Calendar — Forum — Blog

Disclaimer: This report is a factual research summary built from primary sources. It contains no analyst opinions, price targets, ratings, or recommendations. Figures should be re-verified against the original filings before any decision. The author is not your financial adviser.